Amgen (NASDAQ:AMGN) Price Target Increased to $307.00 by Analysts at UBS Group

Amgen (NASDAQ:AMGN – Free Report) had its price target boosted by UBS Group from $284.00 to $307.00 in a report released on Friday, Benzinga reports. The firm currently has a neutral rating on the medical research company’s stock. AMGN has been the subject of a number of other reports. William Blair upgraded Amgen from a […]

Related Keywords

Leerink Partnrs ,Nancya Grygiel ,William Blair ,Acropolis Investment Management ,Opal Wealth Advisors ,Amgen Company Profile ,Morgan Stanley ,Amgen Inc ,Southland Equity Partners ,Marino Stram Associates ,Amgen ,Free Report ,Truist Financial ,Moderate Buy ,Get Free Report ,Equity Partners ,Investment Management ,Wealth Advisors ,Marino Stram ,Amgen Daily ,Nasdaq Amgn ,Amgn ,Medical ,03116210 ,Boost Price Target ,Ubs Group Ag ,